It was found overexpressed in 60 % breast cancer patients, leading to tamoxifen resistance and worse clinical outcome, while the NCOA3 deficiency could suppress the tumor initiation and progression in mice model with breast cancer [32]. Here, NCOA3 is linked to breast carcinoma.